|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2000037535 |
|
最近更新日期: Date of Last Refreshed on: |
2020-10-26 01:05:05 |
|
注册时间: Date of Registration: |
2020-08-28 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
先天性肾脏及尿路畸形的出生缺陷预警及早期精准诊断 |
|
Public title: |
Prediction of Renal Parenchymal Damage of CAKUT |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
先天性肾脏及尿路畸形的出生缺陷预警及早期精准诊断 |
|
Scientific title: |
Protocol for a Cohort Diagnostic Accuracy Study to Develop Prediction of Renal Parenchymal Damage and to Evaluate Accuracy of Renal Function in Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李雅琦 |
研究负责人: |
饶佳 |
|
Applicant: |
Yaqi Li |
Study leader: |
Jia Rao |
|
申请注册联系人电话: Applicant telephone: |
+86 18956006768 |
研究负责人电话: Study leader's telephone: |
+86 021-64932881 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yakee9717@163.com |
研究负责人电子邮件: Study leader's E-mail: |
jiarao@fudan.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市闵行区万源路399号 |
研究负责人通讯地址: |
上海市闵行区万源路399号 |
|
Applicant address: |
399 Wanyuan Road, Minhang District, Shanghai, China |
Study leader's address: |
399 Wanyuan Road, Minhang District, Shanghai, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
复旦大学附属儿科医院 |
||
|
Applicant's institution: |
Children's Hospital of Fudan University |
||
|
研究负责人所在单位: |
复旦大学附属儿科医院 |
||
|
Affiliation of the Leader: |
Children's Hospital of Fudan University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
【2020】363 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
复旦大学附属儿科医院伦理委员会 |
||
|
Name of the ethic committee: |
Institutional Review Board of Children's Hospital of Fudan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-08-27 00:00:00 |
||
|
伦理委员会联系人: |
钱莉玲 |
||
|
Contact Name of the ethic committee: |
Liling Qian |
||
|
伦理委员会联系地址: |
上海市闵行区万源路399号 |
||
|
Contact Address of the ethic committee: |
399 Wanyuan Road, Minhang District, Shanghai, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 021-64931913 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
复旦大学附属儿科医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Children's Hospital of Fudan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市闵行区万源路399号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
399 Wanyuan Road, Minhang District, Shanghai, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
复旦大学附属儿科医院 |
||||||||||||||||||||||
|
Source(s) of funding: |
Children's Hospital of Fudan University |
||||||||||||||||||||||
|
Target disease: |
Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
诊断试验 |
||||||||||||||||||||||
|
Study type: |
Diagnostic test |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
1、确立CAKUT患儿影像学表型-基因型-尿液分子表型谱的迭加分析预测模型,形成CAKUT肾脏发育缺陷和功能损害的精准预警方案。 2、全面评估CAKUT孕前-孕期-生后的高危因素,提出CAKUT高危新生儿的早期诊断优化策略 |
||||||||||||||||||||||
|
Objectives of Study: |
To establish the prediction of the renal damage and renal development deficiency in congenital anomalies of kidney and urinary tract (CAKUT), a diagnostic accuracy study on MRI-DWI combined with urinary microprotein detection is to carried out comparing with DMSA scan as the golden standard for renal damage. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
CAKUT临床及遗传分子学诊断确立患儿: |
||||||||||||||||||||||
|
Inclusion criteria |
Patient that was diagnosed clinically and genetically as: |
||||||||||||||||||||||
|
排除标准: |
1)项目入组3月内不同病因导致肾功能衰竭无法留取到尿液标本的患者; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Patient with renal failure due to different causes but without urine specimen; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-12-01 00:00:00至 To 2024-12-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2020-12-01 00:00:00 至 To 2022-12-01 00:00:00 |
|
诊断试验: Diagnostic Tests: |
|
||||||||||||||||||||||||||||
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由统计人员运用SPSS统计软件,采用随机数字表法生成随机方案。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The statistician uses SPSS, a statistical software, and the random number table method to generate the random scheme. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
共享至国家儿童遗传性肾脏病数据库平台 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Upload to Chinese Children Genetic Kidney Disease Database. Website: www.ccgkdd.com.cn |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表采集,Excel和SPSS管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF, Excel and SPSS |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |